VE303

Vedanta Biosciences Secures $60M to Advance Phase 3 VE303

CAMBRIDGE, Mass., August 6, 2026 Vedanta Biosciences announced it has secured $60 million in funding to accelerate development of...

By cGxPwire Editor
August 7, 2026

Bio-Pharma

Vedanta Biosciences Advances Microbiome Drugs at ESCMID 2026

CAMBRIDGE, Mass., April 9, 2026 Vedanta Biosciences, a late clinical-stage biopharmaceutical company, has announced new scientific presentations showcasing its...

By cGxPwire Editor
April 10, 2026

Bio-Pharma

Vedanta Biosciences Advances VE303 Phase 3 Trial in CDI

CAMBRIDGE, Mass., April 2, 2026 Vedanta Biosciences announced that its pivotal Phase 3 RESTORATiVE303 clinical trial of VE303 will...

By cGxPwire Editor
April 6, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

Vedanta Biosciences Secures $60M to Advance Phase 3 VE303

Vedanta Biosciences Advances Microbiome Drugs at ESCMID 2026

Vedanta Biosciences Advances VE303 Phase 3 Trial in CDI